Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Helix BioPharma Corp.TSX: HBP.TO
Retained Earnings · Q3 FY2026 · quarter ended Apr 2026
Retained earnings remains negative
Q3 FY2026 retained earnings was -CA$218.25M, compared with -CA$214.93M a year earlier.
Context
- Retained earnings amounted to 1020.7% of total assets at the end of Q3 FY2026, down 20280.2 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -1.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
CAD · from the balance sheet
- Latest · FY2025
- (215.88M) CAD
- Year-over-year change
- -2.5%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | (215.88M) | -2.5% |
| FY2024 | 2024-07-31 | (210.67M) | -4.6% |
| FY2023 | 2023-07-31 | (201.41M) | -3.2% |
| FY2022 | 2022-07-31 | (195.12M) | -3.5% |
| FY2021 | 2021-07-31 | (188.55M) | — |
Retained Earnings vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1.5% is the highest of 5, against a peer median of -13.4%.
- Retained earnings amounts to 1020.7% of total assets for HBP.TO, versus a peer median of 435.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | -$91.8M USD | -45.2% | — | 121.9% |
| Apr 2026 | -CA$171.67M CAD | -7.4% | — | 11189.3% | |
| Mar 2026 | -$206.59M USD | -4.2% | — | 157.5% | |
| Apr 2026 | -CA$218.25M CAD | -1.5% | — | 1020.7% | |
| Mar 2026 | -CA$223.89M CAD | -19.4% | — | 712.9% | |
| Peer median (excluding HBP.TO) | — | -13.4% | — | 435.2% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.